• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期尿路上皮癌的挽救性全身治疗:是否正处于重大变革的边缘?

Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?

作者信息

Sonpavde Guru, Bellmunt Joaquim

机构信息

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, USA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, USA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Oncologist. 2015 May;20(5):461-3. doi: 10.1634/theoncologist.2015-0077. Epub 2015 Apr 6.

DOI:10.1634/theoncologist.2015-0077
PMID:25845991
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4425398/
Abstract

This commentary addresses salvage therapy of advanced urothelial carcinoma and the importance of prognostic classification. Patients should be referred to one of the important clinical trials of salvage therapy rather than treatment with marginally active chemotherapeutic agents.

摘要

本评论探讨了晚期尿路上皮癌的挽救治疗以及预后分类的重要性。患者应被转诊至重要的挽救治疗临床试验之一,而非接受疗效欠佳的化疗药物治疗。

相似文献

1
Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?晚期尿路上皮癌的挽救性全身治疗:是否正处于重大变革的边缘?
Oncologist. 2015 May;20(5):461-3. doi: 10.1634/theoncologist.2015-0077. Epub 2015 Apr 6.
2
A new standard of care for advanced-stage urothelial carcinoma.晚期尿路上皮癌的一种新护理标准。
Nat Rev Clin Oncol. 2024 May;21(5):336. doi: 10.1038/s41571-024-00884-0.
3
Therapeutic strategies for upper tract urothelial carcinoma.上尿路尿路上皮癌的治疗策略。
Expert Rev Anticancer Ther. 2018 Aug;18(8):765-774. doi: 10.1080/14737140.2018.1481395. Epub 2018 Jun 8.
4
Editorial Comment to Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.关于治疗前中性粒细胞与淋巴细胞比值作为转移性尿路上皮癌患者生存独立预测因素的编辑评论:一项多机构研究
Int J Urol. 2015 Jul;22(7):643-4. doi: 10.1111/iju.12772. Epub 2015 Apr 22.
5
Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure.对最初无法切除的尿路上皮癌进行手术巩固治疗:治愈的渐进性机会。
Expert Rev Anticancer Ther. 2009 Dec;9(12):1701-3. doi: 10.1586/era.09.146.
6
UTUC in 2017: Emerging evidence on treating upper tract urothelial cancer.2017年上尿路尿路上皮癌:关于治疗上尿路尿路上皮癌的新证据
Nat Rev Urol. 2018 Feb;15(2):73-74. doi: 10.1038/nrurol.2017.203. Epub 2017 Nov 28.
7
Urothelial carcinoma of the upper urinary tracts: current knowledge and future perspectives.上尿路尿路上皮癌:当前认知与未来展望
Minerva Urol Nefrol. 2016 Aug;68(4):348-9.
8
Changing concepts on pathology and therapy for transitional cell carcinoma.移行细胞癌病理学与治疗观念的转变
J Urol. 1995 Nov;154(5):1717-8. doi: 10.1016/s0022-5347(01)66764-8.
9
Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.治疗前中性粒细胞与淋巴细胞比值作为转移性尿路上皮癌患者生存的独立预测指标:一项多机构研究。
Int J Urol. 2015 Jul;22(7):638-43. doi: 10.1111/iju.12766. Epub 2015 Apr 22.
10
Advancements in the clinical management of upper tract urothelial carcinoma.上尿路尿路上皮癌的临床管理进展。
Expert Rev Anticancer Ther. 2019 Dec;19(12):1051-1060. doi: 10.1080/14737140.2019.1698295. Epub 2019 Dec 6.

引用本文的文献

1
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.晚期尿路上皮癌患者接受一线铂类化疗时肿瘤微小RNA谱与预后的相关性
Br J Cancer. 2016 Jun 28;115(1):12-9. doi: 10.1038/bjc.2016.146. Epub 2016 Jun 23.

本文引用的文献

1
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.晚期尿路上皮癌接受挽救性全身治疗患者的改良五因素预后分类
J Urol. 2016 Feb;195(2):277-82. doi: 10.1016/j.juro.2015.07.111. Epub 2015 Aug 17.
2
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.培美曲塞单药治疗铂类耐药晚期尿路上皮癌的安全性和疗效:一项大型单机构经验。
Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6.
3
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.MPDL3280A(抗 PD-L1)治疗可导致转移性膀胱癌的临床活性。
Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.
4
Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.预测晚期尿路上皮癌挽救性全身治疗获益的列线图
BJU Int. 2015 Jun;115(6):854-5. doi: 10.1111/bju.12922. Epub 2015 Jan 21.
5
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.晚期尿路上皮癌挽救治疗的患者入选标准和试验设计。
Clin Genitourin Cancer. 2014 Dec;12(6):395-8. doi: 10.1016/j.clgc.2014.03.016. Epub 2014 Jun 10.
6
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.中性粒细胞与淋巴细胞比值在实体瘤中的预后作用:系统评价和荟萃分析。
J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi: 10.1093/jnci/dju124. Print 2014 Jun.
7
Comprehensive molecular characterization of urothelial bladder carcinoma.尿路上皮膀胱癌的综合分子特征分析
Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.
8
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.以 6 个月无进展生存期作为主要终点,评估新药物作为晚期尿路上皮癌二线治疗的疗效。
Clin Genitourin Cancer. 2014 Apr;12(2):130-7. doi: 10.1016/j.clgc.2013.09.002. Epub 2013 Sep 28.
9
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.纳米白蛋白结合紫杉醇二线治疗转移性尿路上皮癌:单组、多中心、2 期研究。
Lancet Oncol. 2013 Jul;14(8):769-76. doi: 10.1016/S1470-2045(13)70162-1. Epub 2013 May 22.
10
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.基于顺铂化疗治疗转移性尿路上皮癌患者的生存预后模型。
J Natl Cancer Inst. 2013 Apr 3;105(7):499-503. doi: 10.1093/jnci/djt015. Epub 2013 Feb 14.